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Abstract
Personalized medicine could revolutionize how primary care physicians treat chronic disease and 
how researchers study fundamental biological questions. To realize this goal we need to develop 
more robust, modular tools and imaging approaches for in vivo monitoring of analytes. In this 
report, we demonstrate that synthetic nanosensors can measure physiologic parameters with 
photoacoustic contrast, and we apply that platform to continuously track lithium levels in vivo. 
Photoacoustic imaging achieves imaging depths that are unattainable with fluorescence or 
multiphoton microscopy. We validated the photoacoustic results that illustrate the superior 
imaging depth and quality of photoacoustic imaging with optical measurements. This powerful 
combination of techniques will unlock the ability to measure analyte changes in deep tissue and 
will open up photoacoustic imaging as a diagnostic tool for continuous physiological tracking of a 
wide range of analytes.
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Medical imaging and diagnostics are two key pillars of personalized medicine and the study 
of disease. However, in order to advance these fields we need to develop novel approaches 
and technologies for in vivo imaging and monitoring of physiologically important analytes. 
Conventional optical imaging techniques suffer from the limited penetration depth of light 
and the loss of spatial resolution in deep tissue due to scattering. Photoacoustic imaging 1-3 
mitigates many of these shortcomings and achieves imaging depths of up to several 
centimeters with acoustically defined spatial resolution. Many photoacoustic techniques 
focus on imaging either endogenous signals such as hemoglobin 4, or exogenous contrast 
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agents such as carbon nanotubes 5, gold nanoparticles 6 and iron oxide nanoparticles 7. 
These measurements are particularly valuable for examining local oxygenation or tissue 
structure, but there is immense value in the untapped use of photoacoustics as a 
measurement tool to monitor changes in analyte concentrations deep within intact tissue. 
Some development work has focused on the combination of photoacoustics with molecular 
imaging probes for distribution 8, pH 9-10, oxygen/reactive oxygen species 11-12, or 
glucose 13, but these probes are available for limited targets and do not incorporate the 
ability to tune sensor response to desired physiological ranges.
Fluorescent nanosensors are well-established, and multiple distinct designs have proven 
capable of monitoring a wide range of analytes in vitro 14-15 and in vivo 16-19. These 
nanosensors offer several key advantages that make them suitable for continuously tracking 
analyte levels. A great deal of development work has established methods for both 
producing nanosensors and tuning a nanosensor’s analytical performance to physiological 
concentration ranges. These nanosensors are particularly appealing because they have the 
added benefit of a modular design. With the modular optode design, the nanosensor’s target 
analyte, spectral properties, and response range arise from straightforward design choices 
such as component ratios. However, the current design of these optode-based nanosensors 
cannot overcome the limitations of fluorescent imaging, particularly in deep tissues.
In this paper, we formulate, characterize, and validate lithium-sensitive nanosensors for 
photoacoustic measurements and compare to results obtained with fluorescence 
measurements. Lithium is a valuable model system for photoacoustic imaging because 
continuous measurement technologies such as photoacoustics can provide a method to track 
systemic concentrations of therapeutic drugs and improve disease management. Lithium is a 
common treatment for bipolar disorder, but it has both a narrow therapeutic window (0.6 – 
1.2 mM) and a low toxic dose (~ 2 mM) 20-21, demonstrating a need for continuous 
monitoring.
Results
The core mechanism for lithium recognition and signaling in these nanosensors is based on 
the well-established optode approach, demonstrated previously for several ionic and small 
molecule analytes 14, 18, 22-23. In this instance, lithium is recognized by a lithium selective 
crown ether ionophore, Lithium Ionophore VI 24, and extracted from bulk solution into the 
hydrophobic polymer core of the nanosensor (Figure 1). This extraction of a cation into the 
core of the polymer causes a shift in the internal pH of the nanosensor, altering the 
protonation state of a chromoionophore, which alters the optical properties of the 
nanosensor. Both the absorption spectrum and fluorescence intensity of the nanoparticles 
change as a function of lithium concentration. These optical changes occur at visible 
wavelengths, which presents difficulties in obtaining good fluorescent signals for in vivo 
imaging, but represent an opportunity for photoacoustic imaging.
Photoacoustic imaging is based on the absorption of photons by a molecule and the 
conversion to ultrasonic waves via the photoacoustic effect 25. When the absorption 
spectrum of the chromoionophore changes, the photoacoustic spectrum changes accordingly 
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(Figures 1a, 2a). As the lithium concentration increases, the absorbance and photoacoustic 
intensity at 515 nm increases, and the absorbance and photoacoustic intensity at 660 nm 
decreases. Importantly, these changes in photoacoustic intensity result from the nanosensor 
and chromoionophore, because the analyte itself does not possess any intrinsic 
photoacoustic properties. From the measurements at these two peak wavelengths (Figure 
2b), we can form a ratiometric index that increases linearly with lithium concentration but is 
not susceptible to common artifacts such as variation in nanosensor concentration or 
number. Photoacoustics can also be used to image these nanosensors under ~1.5 mm of 
chicken muscle tissue (Figure 2c, 2d). The signal attenuation at 515 nm is larger than at 660 
nm, which decreases the contrast at that wavelength and reduces the ratiometric values for 
the data while remaining linear over the physiologically relevant range of lithium.
Lithium selective nanosensors injected into the skin of mice can be imaged with 
photoacoustic tomography (Figure 3a), but a key advantage of photoacoustics is the ability 
to collect data from the entire tissue volume (Figure 3b, Supporting Video 1). Importantly, 
the data collected in the surface projection is a result of the entire sensor injection, rather 
than the nanosensors closest to the skin surface, as is the case with fluorescence imaging. 
Upon i.p. administration of lithium to the animals at a physiological concentration of 38 
mg/kg (~2.5 mM blood concentration)26, the nanosensor photoacoustic ratio increased by 25 
percent. This clear response to the increasing lithium has a time to peak concentration of 14 
minutes (Figure 3c, Supporting Fig. 17-18) compared with 2 hours for humans 27. It is 
already known that lithium elimination pharmacokinetics are an order of magnitude more 
rapid in mice 28; it is likely that the peak time is also faster due to these increased kinetics. 
Importantly, this data was acquired without blood sampling and from the entire depth of the 
nanosensors, which means the sensors are closer to the capillary bed which should minimize 
response lag time and more accurately reflect blood concentrations.
These multimodal nanosensors generate both fluorescent and photoacoustic signals which 
allow us to compare the two imaging modes for the sensors. Traditionally, these sensors 
have relied on the fluorescence of the chromoionophore directly, which is in the visible 
range. In this work, we shifted the fluorescence to near-IR (NIR) wavelengths to minimize 
optical effects from imaging in tissue (Figure 1b). To accomplish this shift, we incorporated 
an NIR fluorophore (DiR) into the nanosensor formulation used for photoacoustics. This dye 
serves as an internal reference signal and a FRET acceptor from the chromoionophore. 
When directly excited, the NIR intensity from DiR is not responsive to changes in lithium 
concentration, providing a reference signal that controls for a variety of factors, such as 
nanosensor number, injection depth, and sensor migration. When the chromoionophore is 
excited, energy transfer to DiR generates an NIR intensity that changes with lithium 
concentrations, because the fluorescence of the donor (chromoionophore) is responsive to 
lithium. When the ratio of these two signals is calculated, the resulting index is correlated 
with the lithium concentration and controls for other variables, similar to the photoacoustic 
index.
In vivo monitoring of lithium levels is drastically improved relative to traditional 
fluorescence imaging through the use of NIR fluorescence. Figure 4a shows example 
fluorescent images of mice with lithium selective nanosensors injected into their skin. 
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Following administration of lithium via i.p. injection under the same conditions as the 
photoacoustic experiments above, the nanosensor fluorescence ratio increases in a dose-
dependent manner to increasing systemic lithium concentrations (Figure 4b, Supporting Fig. 
15-16). The time to peak concentration, 18 min, is similar to that of photoacoustics, although 
the magnitude of the signal change is 8% as opposed to 25% for photoacoustics at the same 
lithium dose, again highlighting the advantages from photoacoustic imaging and improved 
imaging depth even when compared with NIR fluorescent imaging.
In vitro design, fabrication, and characterization of both photoacoustic and fluorescent 
nanosensors are essential for effective in vivo application. These steps are similar to 
previous reports 18 and are also detailed thoroughly in the supplementary materials 
(Supporting Fig. 2-14). Two key characteristics were tuned during the formulation process: 
sensitivity in the physiological range for lithium (0.5 – 4 mM) 29 and selectivity for the 
nanosensors over sodium. Sensitivity is primarily controlled through selection of the 
chromoionophore and the ratio of the sensor components. Selectivity is controlled through 
the selection of the lithium ionophore and the addition of TOPO (Trioctylphosphine oxide), 
which has been shown to increase lithium selectivity in macroscale optodes 20. We found a 
similar effect of TOPO on the selectivity of nanosensors (Supporting Fig. 2), increasing 
selectivity over sodium to a level suitable for monitoring changes in lithium concentration in 
the background of physiological sodium. As a result, changes of sodium in the physiological 
range do not affect the nanosensor signal. Details on tuning sensor response, final 
formulations, further spectral data, and additional characterization are provided in the 
supplementary materials. The calibration of the response to lithium for the final formulation 
of nanosensors in the background of physiological sodium is shown in Supporting Figure 6. 
The EC50 for the fluorescent sensors is 3.7 mM with a sensitivity of 45 %/log at 2 mM 
lithium compared with 10 mM and 29%/log for photoacoustic imaging. These results are 
similar, indicating that the mechanism underlying sensor response to lithium is decoupled 
from the readout mechanism as expected. Due to the small size of the nanosensors (27 nm 
by DLS, Supporting Fig. 9), the nanosensors are able to respond faster than 15 seconds 
(Supporting Fig. 11), significantly faster than necessary for the dynamics of lithium 
administration. The nanosensors are also reversible (Supporting Fig. 12), which is an 
essential property for in vivo monitoring so the sensors can continuously monitor increases 
and decreases in lithium concentration.
Discussion
This is the first report of photoacoustic imaging to measure therapeutic drug concentrations 
in vivo. The results show a promising improvement over fluorescence imaging of the same 
nanosensors and can image a depth profile with ~200 μm resolution. Imaging nanosensor 
injections in three dimensions solves several problems with current fluorescence-based 
approaches because the depth profile separately measures sensor responses in regions closest 
to the capillary bed. For larger molecules such as glucose, the differences between values 
near the capillary bed and skin surface may differ significantly 30, and photoacoustic 
imaging may provide superior diagnostic power. Fluorescence and photoacoustic 
measurements yielded the same basic response in vitro and lithium kinetics in vivo, 
demonstrating that the multimodal imaging does not alter the mechanism of the sensors and 
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highlighting the robustness of the platform and earlier nanosensor development work. This 
validation is a key step toward the application of these nanosensors for imaging in deeper 
organs such as the brain.
A common limiting factor for time resolution in basic and clinical pharmacokinetic research 
is the need for blood sampling. This is the first in vivo real time tracking of lithium levels 
without blood sampling. Lithium is a common and potent treatment for bipolar disorder, but 
its narrow therapeutic window and low toxic dose make it more difficult to dose than other 
pharmaceutical therapies. A minimally-invasive continuous monitor for blood lithium 
concentrations would be highly useful for dose administration and management 21. 
Nanosensors produce a ratiometric photoacoustic index and a ratiometric fluorescent index 
that both respond to lithium concentrations in vivo. These multiwavelength indexes are less 
affected by sensor concentration and sensor injection depth than single wavelength intensity 
measurements, although still suffer from biases resulting from differential tissue attenuation 
at the two wavelengths. Commonly it is believed that shifting fluorescence wavelengths to 
the NIR will alleviate the effect of tissue absorption and scatter, but the improved index 
change from photoacoustic imaging indicates that this approach is only partially effective. In 
the larger context of continuous physiologic monitoring, this modular nanosensor platform 
translates directly to other electrolytes 16, 31 and small molecules such as histamine 17, with 
future work in our groups directed towards photoacoustic monitoring of these analytes with 
nanosensors. Additionally, this approach should work with other optical and photoacoustic 
imaging configurations (nonlinear optical, tomography, etc.) to obtain necessary resolution 
or imaging depth for particular applications outside of drug monitoring. Future work in our 
groups will determine the maximum penetration depth where we can image nansosensor 
function as well as image with higher spatial resolution. The incorporation of other imaging 
approaches such as SERS (surface-enhanced raman spectroscopy)32, SPECT (single-photon 
emission computed tomography)33, CT (computed tomography)34, MRI (magnetic 
resonance imaging)35, and fluorescence deconvolution36 will also yield value to these 
sensors.
Photoacoustic imaging is much less established than fluorescence imaging, and several 
technical challenges obstruct the widespread adoption of the technique. First, photoacoustic 
imaging instrumentation, not available in most research groups, is more complex than 
fluorescence imaging instrumentation. However, improved light sources and more portable 
imaging setups are under development, and commercial photoacoustic imaging systems are 
starting to appear on the market for preclinical applications 1. Current research efforts in the 
photoacoustics community have begun to focus on increasing the photoacoustic contrast 
from exogenous probes 5, 8. Future work in our groups will focus on developing nanosensors 
with active wavelengths in the NIR region. This will benefit both fluorescence and 
photoacoustic imaging by eliminating much of the background signal and enhancing 
sensitivity of the approach. Despite these current shortcomings, the results herein show that 
photoacoustics is a measurement mode for nanosensors that can provide previously 
unattainable measurement depths, which can have profound effects on chronic disease 
management.
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Methods
Poly(vinyl chloride), high molecular weight (PVC), bis(2-ethylhexyl) sebacate (DOS), 
sodium tetrakis[3,5-bis(trifluoromethyl)phenyl] borate (NaTFPB), 9-Dimethylamino-5-[4-
(15-butyl-1,13-dioxo-2,14-dioxanonadecyl)phenylimino]benzo[a]phenoxazine 
(Chromoionophore VII;CHVII), 6,6-Dibenzyl-1,4,8-11-tetraoxacyclotetradecane (Lithium 
Ionophore VI; LiI VI), trioctylphosphine oxide (TOPO), tetrahydrofuran (THF), 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), dichloromethane (DCM), 9-
Dimethylamino-5-[4-(16-butyl-2,14-dioxo-3,15-
dioxaeicosyl)phenylimino]benzo[a]phenoxazine (chromoionophore II; CHII), N,N-
Dicyclohexyl-N′,N′-diisobutyl-cis-cyclohexane-1,2-dicarboxamide (Lithium Ionophore III; 
LiI III), 2-nitrophenyl octyl ether (NPOE), 2-nitrophenyl phenyl ether (NPPE), and lithium 
chloride were purchased from Sigma Aldrich (St. Louis, MO). 1,2-disteroyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium salt in chloroform 
(DSPE-PEG) was purchased from Avanti Polar Lipids (Alabaster, AL). 1,1'-
Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide(DiR) was purchased from Life 
Technologies (Grand Island, NY) 2-Amino-2-hydroxymethyl-propane-1,3-diol, 2M 
solution, (TRIS, 2M) was purchased from Fisher Scientific (Waltham, MA). Phosphate 
buffered saline (PBS with Ca++ and Mg++, pH=7.4) was purchased from Boston 
Bioproducts(Ashland, MA).
Nanosensor Fabrication
Protocols used in this report are based on those previously described37-38. In brief, the 
process of fabricating optodes and nanosensors starts with formulation of an optode cocktail 
comprising 500 µL THF containing PVC, DOS, and the sensing components. The ratio of 
these components is tuned to control the response of the nanosensors. The formulation of the 
nanosensors used in the manuscript is 60 mg PVC, 120 µL DOS, 20 mg TOPO, 20 mg LiI 
VI, 22 mg NaTFPB, and 2 mg CH VII dissolved in 1 mL of THF. The formulation for 
fluorescence nanosensors also includes 0.5 mg of DiR in each batch.
To fabricate nanosensors from this optode cocktail, 2 mg of DSPE-PEG (80 µL of a 25 
mg/mL in chloroform) was dried in a 4 dram scintillation vial and then resuspended in 5 mL 
PBS with a probe tip sonicator for 30 seconds at 20% intensity (Branson, Danbury CT). 50 
µL of the optode cocktail was combined with 50 µL of dichloromethane, and added to the 
PBS/PEG-lipid solution under probe tip sonication (3 minutes, 20% intensity). The 
nanosensor solution was filtered with a 0.8 µm syringe filter to remove excess polymer (Pall 
Corporation, Port Washington, NY). Nanosensors were sized using dynamic light scattering 
(DLS) with a Brookhaven 90Plus (Brookhaven Instruments, Holtsville, NY). The 
nanosensors were concentrated approximately 30-fold for in vivo experiments and 
approximately 20-fold for in vitro photoacoustic imaging using Amicon Ultra centrifugal 
filters (0.5 mL volume, 50 kDa MWCO, Millipore Corporation, Billerica, MA). In vitro 
fluorescence experiments used unconcentrated nanosensors.
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Fluorescent Nanosensor Characterization
Nanosensors were calibrated in vitro utilizing a Lumina II in vivo imaging system (Caliper 
Life Sciences, Hopkinton, MA). This plate was imaged with two channels. DiR: high lamp 
power, excitation filter centered at 745 nm (30 nm bandpass), emission filter from 810 nm to 
875 nm, and a 1 second exposure. CHVII FRET: high lamp power, excitation filter centered 
at 640 nm (30 nm bandpass), emission filter from 810 nm to 875 nm, and a 1 second 
exposure. For data analysis regions of interest were drawn over each well using Living 
Image 4 software (Caliper Life Sciences) and total fluorescent intensity values were 
obtained for each well. The ratio of the intensities of the two channels (DiR / FRET) was 
calculated and then converted to alpha 23 by normalizing to the ratio obtained in the 
presence of 0.25 mM HCl and 0.25 mM NaOH, which set the maximum protonated and 
deprotonated states for the sensors. The data for the calibration curve was fit to a four 
parameter logistic curve using Prism 6 to determine EC50 and sensitivity.
The bulk of nanosensor formulation and screening experiments examine only the 
chromoionophore fluorescence rather than a ratio of two fluorescent signals. Additionally, 
screening experiments used 10 mM HEPES, 6 mM TRIS as the buffer solution instead of 
PBS. This is to enable quantification of lithium selectivity over sodium. Nanosensors were 
added to a 96 well plate and lithium (or sodium) solutions were then added to the wells to 
final concentrations of 0 mM through 1M and the plate was scanned with a Spectramax M3 
plate reader. Endpoint fluorescence values were obtained at an excitation wavelength of 660 
nm, emission at 705 nm, and a cutoff filter at 665 nm. In experiments where DiR was 
included in the formulation, fluorescence was measured with excitation:emission:cutoff at 
640:780:695 for FRET and 740:780:NA for DiR fluorescence. Fluorescence spectrums were 
acquired using similar settings. Absorbance spectrums were taken between 400 and 850 nm.
To characterize nanoparticle diameter and morphology, scanning electron microscopy 
(SEM) was performed on fluorescent nanosensors. Nanosensors were dried under vacuum 
on conductive adhesive tape attached to 25 mm aluminum SEM mounts from Electron 
Microscopy Sciences (Hatfield, PA). SEM images were taken using a Hitachi S4800 
HRSEM operating at an accelerating voltage of 5.0 kV. Nanoparticle diameter was 
measured using ImageJ.
Photoacoustic System
Two photoacoustic tomography systems were used for this research. For in vitro phantom 
experiments, photoacoustic computed tomography (PACT) was used as previously 
detailed 39-40. Briefly, a tunable optical parametric oscillator laser (basiScan 120, Spectra-
Physics) pumped by an Nd:YAG laser (Brilliant b, Quantel) with 10 Hz pulse repetition rate 
was used to excite photoacoustic waves. Light exiting the laser system was homogenized by 
an optical diffuser and then illuminates the sample. The photoacoustic waves were detected 
by a 512-element circular transducer array (Imasonic) with 5 MHz central frequency. The 
imaging system has 0.10 mm radial resolution and 0.10-0.25 mm tangential resolution 41. 
The image was reconstructed based on back projection algorithm.
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For in vivo monitoring experiments, we used a deep reflection-mode photoacoustic 
tomography system as previously detailed 42. Briefly, a dark-field focusing illumination was 
achieved through a series of optical elements from the same laser source as above. The 
optical fluence at the animal surface was controlled to be below the maximum permissible 
exposure set by the American National Standards Institute 43. A photodiode (SM05PD1A, 
Thorlabs) was used for monitoring and compensating for the fluctuation of the laser energy. 
The excited ultrasound waves were detected by a 10 MHz central frequency focused 
ultrasonic transducer (V315, Panametrics-NDT) and the signals were then amplified by an 
amplifier (5072PR, Panametrics-NDT) and digitized by an oscilloscope (ZT4421, ZTEC 
Instruments). The imaging system was mounted on a linear translation stage (XY-6060, 
Danaher Motion) to acquire three-dimensional images. The spatial resolutions of the system 
are approximately 0.17 mm and 0.29 mm in the axial and lateral directions, respectively.
Photoacoustic In Vitro Characterization
Mixtures of nanosensors and different concentration of lithium were injected into silicone 
tubing. Then these pieces of tubing were sealed by rubber at both sides. The sealed tubing 
was embedded in agar gel and covered by chicken breast tissue for imaging. Based on these 
initial results, we chose imaging parameters for later in vivo imaging to minimize signal 
from vasculature and tissue to focus on the signal from nanosensors alone.
In Vivo Studies
All in vivo studies were approved by the institutional animal care and usage committee 
(IACUC) of Northeastern University. In vivo photoacoustic studies were also approved by 
the institutional animal care and usage committee of Washington University in St. Louis.
In Vivo Photoacoustic Studies
The mice used in this research were Hsd:Athymic Nude-Foxn1nu from Harlan Laboratories. 
Photoacoustic imaging experiments were conducted using the system described above. 
Animals were anesthetized with 1.5% isoflurane in oxygen and 40 µL of nanosensors were 
injected i.d. into the mouse on the back. The animals were imaged with two channels at 
excitation wavelengths 515 nm and 660 nm (the peak wavelengths for the PA signal). 
Baseline raster scan images were acquired at both wavelengths and continuous monitoring 
was done with both wavelengths at the center of the nanosensor injection. Data points were 
acquired approximately every minute after an i.p. injection of 38 mg/kg lithium 
(administered as lithium chloride in PBS, experimental) or a matching volume of PBS 
(control). Images were acquired every minute for approximately one hour. Animals were 
imaged one at a time. All animals were sacrificed after experiments were completed. For 
data analysis of each experiment, an index of the two photoacoustic intensities was 
generated by dividing the 515 nm signal by the 660 nm signal. These ratios were normalized 
to that at the first time point after injection of lithium. These data were linearly interpolated 
to align time and intensity points before averaging. Error bars for lithium dataset represent 
the standard deviation of three animals.
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Fluorescent in vivo Studies
The mice used in this research were male SKH1-E Nude mice from Charles River 
(Wilmington MA). Fluorescent imaging experiments were conducted using a Lumina II in 
vivo imaging system (IVIS). Animals were anesthetized with 2.25% isoflurane in oxygen 
and placed in the animal imager. 30 µL of nanosensors were injected i.d. into the mouse on 
the back. The animals were imaged with two channels. DiR: high lamp power, excitation 
filter centered at 745 nm (30 nm bandpass), emission filter from 810 nm to 875 nm, and a 1 
second exposure. CHVII-FRET to DiR: high lamp power, excitation filter centered at 640 
nm (30 nm bandpass), emission filter from 810 nm to 875 nm, and a 1 second exposure. 
Baseline images were acquired for approximately 30 minutes, followed by an i.p. injection 
of 12 or 38 mg/kg lithium (administered as lithium chloride in PBS, experimental) or a 
matching volume of PBS (control). Images were acquired every minute for approximately 
one hour. The imaging equipment could not image six animals simultaneously, so animals 
were imaged in pairs. All animals were sacrificed after experiments were completed. For 
data analysis of each experiment, a region of interest encompassing the injection area was 
selected and total fluorescent intensity for each channel was recorded. At each time point an 
index was generated by dividing the intensity from DiR channel by the CHVII-FRET 
channel. These ratios were normalized to the first time point before injection of lithium. This 
data was then averaged together across three experimental animals for each lithium 
concentration and six control animals using linear interpolation to align time and intensity 
points before averaging. Error bars represent the standard deviation of these animals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Nanosensors for detecting lithium can be monitored with both photoacoustic (a) and 
fluorescent (b) imaging techniques. Both approaches use multiwavelength ratiometric 
imaging to generate a response that changes with lithium concentration and minimizes 
nonspecific changes. In photoacoustic monitoring, two wavelengths are used to interrogate 
the chromoionophore embedded in the sensors, and the photoacoustic waves from each 
wavelength change as lithium concentration changes. In fluorescent imaging, a near-IR 
fluorophore is added to the sensors. The intensity of FRET from the chromoionophore to the 
near IR dye changes with lithium concentration, whereas directly exciting the near-IR dye 
does not change intensity—serving as a sensing reference. The fundamental mechanism of 
the lithium response (c) is lithium extraction by an ionophore (L) into the core of the 
nanosensor, which deprotonates a chromoionophore (CH+), changing the optical properties 
of the nanosensor. An additive (R-) balances the charge inside the sensor.
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Figure 2. 
Responses of photoacoustic nanosensors to lithium within physiological ranges. The 
photoacoustic spectrum (a) has two peaks centered at 515 and 660 nm. The 515 peak 
increases with lithium concentrations, and the 660 peak decreases. In vitro measurement of 
this ratio (b) responds to lithium and is insensitive to common confounding factors such as 
concentration of nanosensors. Photoacoustic imaging of nanosensors under a 1.5 mm thick 
layer of chicken tissue (c) shows signal attenuation of the 515 nm peak, while retaining the 
ratiometric lithium response (d). PA: photoacoustics.
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Figure 3. 
Photoacoustic nanosensors imaged in a small animal model. Dual wavelength images of the 
nanosensor injection using photoacoustic tomography (a) clearly show the boundary of the 
injection. A depth profile (b) taken along the line below the red asterisk in (a) shows the 
nanosensor injection in the tissue. The response of nanosensors to systemic lithium 
administration (c) for three animals yields a time to maximum lithium of 14 minutes 
(lithium n=3, vehicle n=1).
Cash et al. Page 14
ACS Nano. Author manuscript; available in PMC 2016 February 24.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
Fluorescent nanosensors for lithium yield similar results to photoacoustic nanosensors 
despite having a different readout mechanism. The images of both wavelengths (a) 
demonstrate the excellent signal to background obtained with near IR imaging, and the 
nanosensor measurement of absorption kinetics (b) yields a time to peak lithium of 18 min, 
similar to that measured with photoacoustics. The response is dose-dependent, with 
increases in lithium yielding higher signal. (n=3 for each lithium curve, n=6 for vehicle)
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